May 22, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
From the National Cancer Institute (NCI)
Cancer Research in the Era of COVID-19
National Cancer Institute Logo
NCI Deputy Director Dr. Dinah S. Singer emphasizes critical aspects of her recent presentation at the virtual 2020 AACR annual meeting. She discusses the impact that the COVID-19 crisis has had on NCI and the extramural community. Dr. Singer also provides an overview of NCI’s efforts to address the pandemic by pivoting some cancer research activities to focus on COVID-19.
COVID-19 Funding Opportunities and Notices
Member/Center Highlights
ASCO Virtual Scientific Program 2020: Highlights from the Case CCC
The American Society of Clinical Oncology (ASCO) Annual Meeting will be held virtually in two parts this year. The Virtual Scientific Program will take place Friday, May 29 through Sunday, May 31, and the Virtual Education Program will be held August 8-10. Oral abstract, poster discussion and poster sessions as well as track-based Clinical Science Symposia, will be available on-demand at 8:00 am ET, Friday, May 29. The virtual meeting will provide an engaging lineup of scheduled and on-demand scientific content offering the opportunity to learn and collaborate across a variety of approaches, disciplines, and specialties. Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days.
The Case Comprehensive Cancer Center (Case CCC) has compiled a list of plenary sessions, clinical science symposia, oral abstract sessions, poster and poster discussion sessions, as well as publication-only abstracts from Cleveland-based institutions including Cleveland Clinic, University Hospitals and Case Western Reserve University.
Spartans Step Up: Understanding COVID-19
Case Comprehensive Cancer Center Director Stan Gerson, MD recently moderated a discussion organized by the Case Western Reserve University Alumni Association.

Dr. Gerson is joined by Heidi Gullett, MD, MPH and Peter Tippett, MD, PhD as they highlight both local and university efforts to understand and combat the disease.
Tesar among 20 scientists nationally to receive National Institute of Neurological Disorders and Stroke Research Program Award
The Case Comprehensive Cancer Center (Case CCC) extends congratulations to Paul Tesar, PhD as he is among 20 researchers nationally to receive an R35 Research Program Award from the National Institute of Neurological Disorders and Stroke.

Dr. Tesar is professor of genetics and genome sciences and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at Case Western Reserve University’s School of Medicine and a member of the Case CCC's GI Cancer Genetics and Molecular Oncology Programs.
Multi-Center Clinical Trial Finds New Blood Test Accurately Detects Over 50 Types of Cancer
From Cleveland Clinic: An ongoing, multi-center clinical trial has found that a new blood test can accurately detect more than 50 types of cancer while still in the early stages – before any clinical signs or symptoms of the disease.

According to the results published recently in the Annals of Oncology , in cases where the test detected cancer, it determined where it was located in the body with 93 percent accuracy. The test has a 0.7 percent false positive rate, meaning that only less than 1 percent of people would be wrongly identified as having cancer.

Eric Klein, MD is chairman of Cleveland Clinic's Glickman Urological & Kidney Institute, senior author of the Annals of Oncology paper, and a member of the Case Comprehensive Cancer Center's GU Malignancies Program. Klein is co-principal investigator of Cleveland Clinic's portion of the study along with Taussig Cancer Institute oncologist and vice chair for research, Mikkael Sekeres, MD. Dr. Sekeres is also Associate Director for Clinical Research at the Case CCC.
Eric Klein
Mikkael Sekeres headshot
Team Case CCC "rides" on into Virtual VeloSano 2020!
Originally scheduled for July 17-19, 2020 in Cleveland, OH, VeloSano 7 is evolving into Virtual Velosano to keep our community safe and healthy during the COVID-19 pandemic. While we won't be able to unite in person this summer, we will continue fundraising as the need for cancer research is more important than ever.

Our continuing goal is to bring sustainable funding to cancer research by enlisting the passion and energy of thousands of people who wish to give back... including YOU! We raised nearly $94,000 in 2019 and every dollar goes directly toward cancer research. In our six years of participation, more than $1,000,000 of VeloSano fundraising totals have come back to the Case CCC to award researchers as pilot funding for cancer research projects.
Case CCC COVID-19 Resource Hub
As the COVID-19 outbreak progresses, the Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email
What's Coming Up
Mark Your Calendar
Virtual Race for The Place 2020
May 29 - June 7, 2020
Facebook and Instagram Live

The Gathering Place is hosting its annual "Race for the Place" 5K and 1-mile run/walk virtually from Friday May 29 to National Cancer Survivors Day, Sunday, June 7. Proceeds from Race for the Place help support their free programs and services.

For the safety of participants and the community and in light of the ongoing concerns around COVID-19, The Gathering Place has made the decision to hold a virtual Race for the Place. They have compiled virtual race ideas and will host their Cancer Survivor Ceremony at 9:00 am Sunday, June 7 on Facebook and Instagram Live.

Race for the Place is a particularly important event for The Gathering Place. It is their only annual fundraiser and provides significant financial support to keep their programs and services free of charge to help individuals and families cope with the impact of cancer in their lives. COVID-19 has not stopped the needs of our participants and they continue to provide free programs every day through GoToMeeting, Zoom, the telephone and Facebook Live.

The Gathering Place is a caring community that supports, educates and empowers individuals and families currently coping with the impact of cancer in their lives through programs and services provided free of charge.
Save The Date: Annual Scientific Retreat (Members and Trainees Only)
July 23-24, 2020

The Case Comprehensive Cancer Center invites all members and trainees to mark their calendars for Thursday, July 23 and Friday, July 24, 2020 for our annual scientific retreat!

We will once again host TED talks from prominent Cleveland researchers and highlight research from each of our scientific programs. As in past years, attendees will hear a cancer center update from Director Stan Gerson.

We are also looking forward to a keynote presentation from Timothy Rebbeck, PhD, the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute. Dr. Rebbeck is founding director of the Zhu Family Center for Global Cancer Prevention at the Harvard TH Chan School of Public Health and leads the Cancer Outreach and Engagement activities for the Dana-Farber Harvard Cancer Center.

Mindful that we must do everything we can to keep our cancer center community safe and healthy, we are planning an alternate abridged virtual agenda as we will not be able to gather in-person in July. Please save the dates at this time, and we will provide additional details of the retreat's format and agenda in the weeks to come.

Please contact Mary Wright ( should you have any questions about the retreat.
Save The Date: Artificial Intelligence in Oncology Symposium 2020
October 19-20, 2020
Tinkham Veale University Center, CWRU

The second annual Artificial Intelligence in Oncology Symposium will bring together experts in AI and machine learning this October at Case Western Reserve University.

Geraldine McGinty, MD, MBA, FACR will present the symposium keynote, "Fostering a Strong Ecosystem for AI in Medical Imaging." Dr. McGinty is an internationally recognized expert in imaging economics, Chair of the American College of Radiology Board of Chancellors and Chief Strategy and Contracting Officer at Weill Cornell Medicine in New York City.
Additional Upcoming Events
AACR Virtual Annual Meeting: Part II
June 22-24, 2020
The AACR Virtual Annual Meeting II, June 22-24, will feature the originally planned Opening Plenary Session that explores the range of impactful cancer research and clinical translation; award lectures from individuals who have made extraordinary contributions to the cancer field; a special talk from National Cancer Institute Director Ned Sharpless, MD; and thousands of proffered papers in minisymposia and on an e-poster platform.
12th Annual AACI Clinical Research Innovation (CRI) Meeting
July 7-8, 2020
Registration is now open for the 12th Annual AACI CRI Meeting, Cancer Clinical Research: Focus on the Future.

Registration for the two-day, virtual meeting is free for AACI cancer center members and sustaining members. AACI is working to ensure that the online meeting, scheduled for July 7-8, will still deliver the innovative, quality education that its members have enjoyed at prior CRI annual meetings.

More information, including the program and registration, is now available on the CRI meeting website.
Funding Opportunities
Pre-Proposal Deadline: May 22, 2020
Full Proposal Deadline: June 15, 2020
The Technology Validation and Start Fund, funded by the Ohio Third Frontier, aims to accelerate and fund the translation of promising technologies into the marketplace through Ohio start-up companies with the eventual goal of creating greater economic growth. Since 2017, CWRU has received yearly awards of $500,000, which are administered by the Technology Transfer Office as the CWRU TVSF Program (CTP) to advance a number of selected programs over a 12-month period. Projects must have already advanced beyond basic research and should have the equivalent of a laboratory-scale proof of concept prior to applying for funding.

All proposals must fall into one of these State of Ohio's technology focus areas:
  • Biomedical/Life Sciences
  • Advanced Materials
  • Energy
  • Software/Information Technology
  • Sensors
  • Advanced Manufacturing

Funding: $100,000 ($50,000 from CTP + $50,000 cost match by awardees)
Funding Period: 12 months
Funding Start Date: August 2020

Pre-proposals should be submitted to using the template.
Internal LOI deadline: Sunday, June 21, 2020
The Case Comprehensive Cancer Center has been invited to submit applications from junior faculty for the Gabrielle's Angel Foundation 2020 Medical Research Awards. Gabrielle’s Angel Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood.

The awards provide $75,000 of support per year over three years, not to exceed $225,000. Applications in conventional and integrative research are being accepted.

Interested candidates are asked to submit an LOI (including PI contact information and an abstract/project summary) and biosketch to by Sunday, June 21, 2020. Contact with questions.
NCCN logo
National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Eli Lilly and Company, to offer an opportunity to support preclinical, clinical and correlative studies, as well as real world evidence evaluation, of abemaciclib in the management of breast cancer. The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of proposals.

The overall aim is to create innovative research and new knowledge in the area of de novo and acquired resistance to CDK 4 & 6 inhibitors. Proposals submitted in response to this RFP may assess predictive markers, and provide data useful in guiding further development of abemaciclib and novel rational combination therapies to overcome resistance to CDK 4 & 6 inhibitors.

Proposals are due by 11:59 PM ET, Friday, July 10, 2020. If you have any questions regarding this RFP, please direct them in writing to Nicole Kamienski at with the subject line, “2020 Abemaciclib Project.”
Deadline: August 12, 2020
National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity that will support NCCN Member Institution faculty in studies of axitinib. The intent of this RFP is to encourage NCCN Member Institutions to submit clinical research proposals specifically in the treatment of melanoma, hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of proposals.

The overall aim is to develop innovative trials that will evaluate the role of axitinib in the treatment of melanoma, HCC and CRC. It is hoped proposals submitted in response to this RFP will be useful in guiding further development of axitinib in combinations with other therapies. Studies with correlative objectives will be accepted, but correlative measures alone cannot be the primary endpoint(s).

To be considered for funding, proposals must be submitted by 11:59 pm ET on Wednesday, August 12, 2020. Please direct questions regarding this RFP to Nicole Kamienski at with the subject line, “2020 Axitinib Project.”
In The News
Columbus Dispatch - May 15, 2020
“All it takes is one individual who is asymptomatic coming within arm’s distance of someone else to start another cluster," said Mark Cameron, PhD, warning that Ohioans are vulnerable to new COVID-19 cases if we're not careful. Dr. Cameron an associate professor in the department of population and quantitative health sciences at Case Western Reserve University and a member of the  Case CCC's Hematopoietic and Immune Cancer Biology Program.
Targeted Oncology - May 19, 2020
"I think it’s important to remind our audience that the management of any cancer, specifically prostate cancer, cannot be done by one person alone. I do believe in the importance of putting the right team of people around the patient with one goal. make sure that we include the right team of people supporting those patients’ needs to maximize the outcomes," says University Hospitals' Jorge Garcia, MD in a video for Targeted Oncology , providing insight on a case of a man with MCRPC and assessing the classes of agents currently available as treatment options.
From The NIH
Weekly NIH Funding Opportunities and Notices

Please note that this Notice rescinds and replaces similar information that was previously published (on March 3, 2020) in NOT-CA-20-033, "Notice on Policy Regarding Minimum Level of Effort for NCI-Funded Awards"

Funding Opportunities

Deadline: Standard dates apply. The first standard application due date for this FOA is June 16, 2020

Deadline: September 11, 2020

Deadline: August 21, 2020

Deadline: September 30, 2020

Deadline: September 4, 2020

Deadline: September 30, 2020

Deadline: September 4, 2020
Have something to share?
Use the button below to submit all your news, events, announcements and communications requests to the Case CCC Marketing and Communications team!